1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients.
1st Biotherapeutics has raised $21.9M in total funding. The most recent round was Series D. The last funding was announced in January 2026.
1st Biotherapeutics's investors include Ligachem Bio, Wanted Lab Partners, Gurum Investment-Double Capital, Korea Investment & Securities, Shinhan Venture Investment.
1st Biotherapeutics is headquartered in Seongnam, South Korea.
1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients.
1st Biotherapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"1st Biotherapeutics — Funding & Investors." VCBacked, January 26, 2026, https://www.vcbacked.co/company/1st-biotherapeutics. Accessed July 19, 2026.
VCBacked. (2026). 1st Biotherapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/1st-biotherapeutics
{{cite web |title=1st Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/1st-biotherapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated